CHINOOK THERAPEUTICS INC's ticker is KDNY and the CUSIP is 16961L106. A total of 77 filers reported holding CHINOOK THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 2.12 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2023 | $31,045,127 | +2453.4% | 808,046 | +1438.5% | 0.01% | +1200.0% |
Q1 2023 | $1,215,838 | -11.6% | 52,520 | 0.0% | 0.00% | 0.0% |
Q4 2022 | $1,376,024 | +99.4% | 52,520 | +49.5% | 0.00% | – |
Q3 2022 | $690,000 | +12.4% | 35,120 | 0.0% | 0.00% | – |
Q2 2022 | $614,000 | +11.0% | 35,120 | +3.8% | 0.00% | – |
Q1 2022 | $553,000 | +0.5% | 33,820 | +0.3% | 0.00% | – |
Q4 2021 | $550,000 | +36.5% | 33,720 | +6.6% | 0.00% | – |
Q3 2021 | $403,000 | -9.6% | 31,620 | 0.0% | 0.00% | – |
Q2 2021 | $446,000 | +18.6% | 31,620 | +30.6% | 0.00% | – |
Q1 2021 | $376,000 | -2.1% | 24,220 | 0.0% | 0.00% | – |
Q4 2020 | $384,000 | – | 24,220 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Samsara BioCapital, LLC | 5,161,888 | $135,241,466 | 29.11% |
Octagon Capital Advisors LP | 2,551,703 | $66,854,619 | 10.41% |
Affinity Asset Advisors, LLC | 818,035 | $21,432,517 | 8.40% |
Frazier Life Sciences Management, L.P. | 4,345,559 | $113,853,646 | 7.08% |
Saturn V Capital Management LP | 423,177 | $6,728,298 | 5.58% |
Altium Capital Management LP | 385,000 | $10,087,000 | 5.13% |
Deep Track Capital, LP | 3,000,000 | $78,600,000 | 3.30% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 340,389 | $8,914,788 | 2.75% |
Vivo Capital, LLC | 872,151 | $22,850 | 2.63% |
Nan Fung Group Holdings Ltd | 113,950 | $2,985,490 | 2.06% |